BRPI0506953A - utilização de ao menos um inibidor de proteases, e, produto farmacêutico - Google Patents

utilização de ao menos um inibidor de proteases, e, produto farmacêutico

Info

Publication number
BRPI0506953A
BRPI0506953A BRPI0506953-0A BRPI0506953A BRPI0506953A BR PI0506953 A BRPI0506953 A BR PI0506953A BR PI0506953 A BRPI0506953 A BR PI0506953A BR PI0506953 A BRPI0506953 A BR PI0506953A
Authority
BR
Brazil
Prior art keywords
protease
hyperalgesia
colon
pharmaceutical product
junctions
Prior art date
Application number
BRPI0506953-0A
Other languages
English (en)
Inventor
Lionel Bueno
Original Assignee
Rytek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rytek filed Critical Rytek
Publication of BRPI0506953A publication Critical patent/BRPI0506953A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE O MENOS UM INIBIDOR DE PROTEASES, E, PRODUTO FARMACêUTICO" O presente pedido refere-se a composições e métodos para o tratamento de patologias intestinais. Ele refere-se igualmente a composições e métodos que permitem regular permeabilidade paracelular do epitélio intestinal. As composições e os métodos da invenção repousam notadamente na utilização de inibidores de proteases que modulam a abertura das junções firmes do epitélio intestinal. A invenção é utilizável para tratamento preventivo ou curativo de patalogias variadas, tais como os problemas funcionais digestivos (PFD),mais particulamente os problemas funcionais intestinais (PFI) que acarretam uma hiperalgesia e notadamente a síndrome do intestino irritável (SII), nos mamíferos, notadamente os humanos.
BRPI0506953-0A 2004-01-19 2005-01-18 utilização de ao menos um inibidor de proteases, e, produto farmacêutico BRPI0506953A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400446A FR2865133B1 (fr) 2004-01-19 2004-01-19 Compositions pour le traitement de pathologies digestives
PCT/FR2005/000108 WO2005077406A1 (fr) 2004-01-19 2005-01-18 Inhibiteurs ded proteases pour le traitement de pathologies digestives

Publications (1)

Publication Number Publication Date
BRPI0506953A true BRPI0506953A (pt) 2007-06-26

Family

ID=34707923

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506953-0A BRPI0506953A (pt) 2004-01-19 2005-01-18 utilização de ao menos um inibidor de proteases, e, produto farmacêutico

Country Status (13)

Country Link
US (1) US20080286355A1 (pt)
EP (1) EP1708740B1 (pt)
JP (1) JP2007518779A (pt)
KR (1) KR20060127983A (pt)
CN (1) CN1909919A (pt)
AT (1) ATE482718T1 (pt)
AU (1) AU2005211965A1 (pt)
BR (1) BRPI0506953A (pt)
CA (1) CA2552638A1 (pt)
DE (1) DE602005023834D1 (pt)
FR (1) FR2865133B1 (pt)
IL (1) IL176733A0 (pt)
WO (1) WO2005077406A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
CN107468698A (zh) * 2017-08-21 2017-12-15 滨州医学院 地瑞那韦减轻伊立替康毒性的医药新用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
EP0958833A1 (en) * 1998-05-20 1999-11-24 Erasmus Universiteit Rotterdam Methods and means for preventing or treating inflammation
US6617426B1 (en) * 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
ITTO20010110A1 (it) * 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
AU2002346594A1 (en) * 2001-12-14 2003-06-30 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
WO2003077893A2 (fr) * 2002-03-15 2003-09-25 Rytek Compositions pour le traitement de pathologies fonctionnelles digestives
WO2004011654A1 (ja) * 2002-07-31 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. 新規セリンプロテアーゼ
ATE353633T1 (de) * 2002-12-19 2007-03-15 Pharmacia Corp Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält

Also Published As

Publication number Publication date
EP1708740A1 (fr) 2006-10-11
KR20060127983A (ko) 2006-12-13
AU2005211965A1 (en) 2005-08-25
JP2007518779A (ja) 2007-07-12
FR2865133A1 (fr) 2005-07-22
IL176733A0 (en) 2006-10-31
DE602005023834D1 (de) 2010-11-11
ATE482718T1 (de) 2010-10-15
CA2552638A1 (fr) 2005-08-25
US20080286355A1 (en) 2008-11-20
WO2005077406A1 (fr) 2005-08-25
CN1909919A (zh) 2007-02-07
EP1708740B1 (fr) 2010-09-29
FR2865133B1 (fr) 2008-01-18

Similar Documents

Publication Publication Date Title
NZ598778A (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
BRPI0513847A (pt) formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
MA28436B1 (fr) Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
EA201001523A1 (ru) Ингибиторы матриксной металлопротеазы на основе арилсульфонамида
SG171649A1 (en) Dpp iv inhibitor formulations
MA29860B1 (fr) Modulateurs du metabolisme et le traitement de troubles s'y rapportant
ATE380175T1 (de) Pyrrolidine als dipeptidyl peptidase inhibitoren
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
NO20062739L (no) Kontrollert frigivining av topirimat i flytende doseringsform
NO20084852L (no) MGLUR5 modulatorer V
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0517846A (pt) azaindolcarboxamidas
BRPI0710483A8 (pt) composições e kits úteis para o tratamento de doenças respiratórias
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
CL2008000613A1 (es) Uso del acido (s,s)-(1-aminometil-3,4-dimetil-ciclopentil)-acetico para preparar un medicamento util para tratar tinnitis en un mamifero.
BR112012010252A2 (pt) variantes de glicosilação de anticorpo
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
EA200900920A1 (ru) Соединения и композиции как ингибиторы активирующей канал протеазы
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
ATE406903T1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
DE602007014400D1 (de) Behandlung pervasiver entwicklungsstörungen
PT1071704E (pt) Novos inibidores e reguladores negativos das metaloproteinases da matriz

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.